Deal could put FDA reps in China

Share this article:

A deal between the US and China could mean more FDA inspection of manufacturing plants. Regulatory Focus reports that the countries struck a deal Dec. 5 that officials say will mean “a substantial increase in the number of US food and drug inspectors” on site.

The news could mean a new rash of Warning Letters to read up on: RF notes that on-site inspections in India, for example, netted six Warning Letters in 2012, and inspectors also put a dent in businesses including Wockhardt and Fresenius Kabi, after finding problems with their facilities.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.